How to Improve Detection and Treatment of Diabetic Retinopathy

Pardue, Machelle T.

Title:

How to Improve Detection and Treatment of Diabetic Retinopathy

dc.contributor.author	Pardue, Machelle T.
dc.contributor.corporatename	Georgia Institute of Technology. Neural Engineering Center	en_US
dc.contributor.corporatename	Georgia Institute of Technology. Wallace H. Coulter Dept. of Biomedical Engineering	en_US
dc.date.accessioned	2017-04-10T17:08:47Z
dc.date.available	2017-04-10T17:08:47Z
dc.date.issued	2017-03-27
dc.description	Presented on March 27, 2017 at 11:00 a.m. in the Engineered Biosystems Building (EBB), room 1005.	en_US
dc.description	Machelle Pardue is a professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. Her research interestss are neuroprotective treatments, retinal mechanisms of refractive development, diabetic retinopathy.	en_US
dc.description	Runtime: 53:29 minutes	en_US
dc.description.abstract	Diabetic retinopathy (DR) is the leading cause of blindness in working age adults. DR is clinically diagnosed by late stage vascular changes in the retina. Detecting early stage retinopathy prior to the onset of these clinical findings would greatly impact the management and treatment of DR. We have identified several tests that show dysfunction in the retina prior to the onset of vascular lesions induced by diabetes. Using novel stimuli with the electroretinogram, we have determined that rod photoreceptor function is most vulnerable to diabetes. Our studies show similar delays in rodent models of diabetes and diabetic patients, prior to clinically diagnosed DR, suggesting a potential screening tool. In addition, we have shown that spatial frequency and contrast sensitivity thresholds decline prior to vascular changes when tested with moving gratings. Finally, we have demonstrated the application of reactive fluorescent tags to detect reactive oxygen species in the retina, providing another possible screening tool for DR. The detection of early stage DR opens a therapeutic window for neuroprotective agents that could slow or halt the progression of disease. We have demonstrated that L-DOPA or exercise treatments are promising interventions to slow the progression of DR and preserve visual function.	en_US
dc.format.extent	53:29 minutes
dc.identifier.uri	http://hdl.handle.net/1853/56626
dc.language.iso	en_US	en_US
dc.relation.ispartofseries	GT Neuro Seminar Series
dc.subject	Diabetic retinopathy	en_US
dc.subject	Dopamine	en_US
dc.subject	Exercise	en_US
dc.title	How to Improve Detection and Treatment of Diabetic Retinopathy	en_US
dc.type	Moving Image
dc.type.genre	Lecture
dspace.entity.type	Publication
local.contributor.author	Pardue, Machelle T.
local.contributor.corporatename	Neural Engineering Center
local.relation.ispartofseries	GT Neuro Seminar Series
relation.isAuthorOfPublication	c0521c82-367a-4016-94d3-b5a1afd859c7
relation.isOrgUnitOfPublication	c2e26044-257b-4ef6-8634-100dd836a06c
relation.isSeriesOfPublication	608bde12-7f29-495f-be22-ac0b124e68c5